Tooth Discoloration in Patients With Neonatal Diabetes After Transfer Onto Glibenclamide
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To assess if tooth discoloration is a novel side effect of sulfonylurea therapy in patients with permanent neonatal diabetes due to mutations in KCNJ11. RESEARCH DESIGN AND METHODS: A total of 67 patients with a known KCNJ11 mutation who had been successfully transferred from insulin injections onto oral sulfonylureas were contacted and asked about the development of tooth discoloration after transfer. RESULTS: Altered tooth appearance was identified in 5 of the 67 patients. This was variable in severity, ranging from mild discoloration/staining (n = 4) to loss of enamel (n = 1) and was only seen in patients taking glibenclamide (glyburide). CONCLUSIONS: These previously unreported side effects may relate to the developing tooth and/or to the high local concentrations in the children who frequently chewed glibenclamide tablets or took it as a concentrated solution. Given the multiple benefits of sulfonylurea treatment for patients with activating KCNJ11 mutations, this association warrants further investigation but should not preclude such treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gloyn, A. L., Pearson, E. R., Antcliff, J. F., Proks, P., Bruining, G. J., Slingerland, A. S., Howard, N., Srinivasan, S., Silva, J. M. C. L., Molnes, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032922 · Cited by 1,137
Self-citationSwitching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations
Pearson, E. R., Flechtner, I., Njølstad, P. R., Malecki, M. T., Flanagan, S. E., Larkin, B., Ashcroft, F. M., Klimes, I., Codner, E., Iotova, V., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061759 · Cited by 988 · cited 3×
“These subjects and their genotypes have previously been reported (1-3).”
BackgroundSelf-citationDiagnosis and treatment of neonatal diabetes: an United States experience†
Støy, J., Greeley, S. A. W., Paz, V. P., Ye, H., Pastore, A. N., Skowron, K. B., Lipton, R. B., Cogen, F. R., Bell, G. I., Philipson, L. H., et al. (2008) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2008.00433.x · Cited by 126
Self-citation
Cited by
Hattersley, A. T., Greeley, S. A. W., Polak, M., Rubio-Cabezas, O., Njølstad, P. R., Mlynarski, W., Castano, L., Carlsson, A., Raile, K., Chi, D. V., et al. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12772 · Cited by 319
“The only side effects reported to date are transient diarrhea and staining of the teeth.(83,84) Some brain imaging studies have shown that sulfonylurea drugs may penetrate blood-brain barrier, but maintenance of levels may limit benefit.”
Self-citationThe diagnosis and management of monogenic diabetes in children and adolescents
Hattersley, A., Bruining, J., Shield, J., Njolstad, P., & Donaghue, K. C. (2009) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2009.00571.x · Cited by 255
Greeley, S. A. W., Polak, M., Njølstad, P. R., Barbetti, F., Williams, R., Castano, L., Raile, K., Chi, D. V., Habeb, A., Hattersley, A. T., et al. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13426 · Cited by 211
Self-citationThe diagnosis and management of monogenic diabetes in children and adolescents
Rubio-Cabezas, O., Hattersley, A. T., Njølstad, P. R., Mlynarski, W., Ellard, S., White, N., Chi, D. V., & Craig, M. E. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12192 · Cited by 196
Self-citationNeonatal Diabetes and the K ATP Channel: From Mutation to Therapy
Ashcroft, F. M., Puljung, M. C., & Vedovato, N. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2017.02.003 · Cited by 106
Metadata
- Authors
- Kumaraguru, J., Flanagan, S. E., Greeley, S. A. W., Nuboer, R., Støy, J., Philipson, L. H., Hattersley, A. T., & Rubio-Cabezas, O.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-05-12
- Volume
- 32
- Issue
- 8
- Pages
- 1428-1430
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2112392308
- Cited by
- 41
- References
- 3
- FWCI
- 2.61
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.